Capricor Therapeutics (NASDAQ:CAPR) Announces Quarterly Earnings Results, Beats Expectations By $0.15 EPS

Capricor Therapeutics (NASDAQ:CAPR) announced its quarterly earnings results on Wednesday. The biotechnology company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.15, Zacks reports. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The company had revenue of $11.13 million during the quarter, compared to analysts’ expectations of $9.87 million.

Capricor Therapeutics Trading Up 17.5 %

CAPR stock opened at $14.36 on Friday. The stock has a market cap of $652.95 million, a price-to-earnings ratio of -13.55 and a beta of 4.10. The business’s 50-day moving average is $14.06 and its 200 day moving average is $14.50. Capricor Therapeutics has a 12-month low of $3.52 and a 12-month high of $23.40.

Wall Street Analyst Weigh In

Several research firms recently issued reports on CAPR. Cantor Fitzgerald reiterated an “overweight” rating and issued a $30.00 target price on shares of Capricor Therapeutics in a research note on Thursday. HC Wainwright reiterated a “buy” rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a research report on Monday. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, Capricor Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.